Prognosis
Astra’s Antibody Cocktail Fails to Stop Covid-19 in Study
- Drug was only 33% effective at preventing symptomatic disease
- Astra has five more trials looking at other uses for cocktail
This article is for subscribers only.
AstraZeneca Plc’s antibody cocktail was only 33% effective at preventing symptomatic Covid-19 in people who had been exposed to the virus, failing a study that was key to the drugmaker’s pandemic push.
The trial of 1,121 adult volunteers looked at whether the long-acting antibody combination could protect people who had recently been in contact with the SARS-CoV-2 virus in places like care homes. The company said it’s running other studies of the medicine that could help clarify the findings.